Iambic Therapeutics IPO

Iambic Therapeutics, based in San Diego, redefines drug discovery by combining human ingenuity with the power of AI. Emphasizing AI-driven design and automation, the company is a pioneer in creating data-efficient, physics-informed AI models. Iambic Therapeutics achieves more reliable and accurate modeling by incorporating physics principles into AI architectures, enabling deeper exploration in chemical space and accelerating the journey toward innovative medical solutions.

Register for Details

For more details on financing and valuation for Iambic Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Iambic Therapeutics

To invest in Iambic Therapeutics pre-IPO

Can you invest in Iambic Therapeutics pre-IPO?

Iambic Therapeutics is a privately held company and is not publicly traded, therefore investing in Iambic Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Iambic Therapeutics before it goes public?

You can seek to sell your shares in Iambic Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Iambic Therapeutics shares?

To determine the value of your Iambic Therapeutics shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Iambic Therapeutics shares. You can also learn more about how to sell your private shares before getting started.

Is Iambic Therapeutics a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Iambic Therapeutics potential IPO

Will Iambic Therapeutics go IPO?

Iambic Therapeutics has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Iambic Therapeutics’ IPO price?

The Iambic Therapeutics IPO price does not exist at this time, as Iambic Therapeutics is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Iambic Therapeutics register for Forge Markets, today.

When was Iambic Therapeutics founded?

Iambic Therapeutics was founded in 2019.

What is Iambic Therapeutics funding to date?

Iambic Therapeutics has raised $1.16B to date.

Who are Iambic Therapeutics’s major investors?

Nexus Ventures
Orbimed
Undisclosed Investors
Tao Capital Partners
Abingworth
Illumina Ventures
Nexus Venture Partners
Qatar Investment Authority
Catalio Capital Management
Freeflow
Tao Capital
Ascenta Capital
Nvidia
Coatue Management
Gradiant Corporatoin
Exor Ventures
Mubadala Capital
Sequoia Capital
Coatue
Shanda

Iambic Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
06/18/2024 Series B-2 $50MM $xx.xx $382.7MM Abingworth, Coatue, Exor Ventures, Illumina Ventures, Mubadala Capital, Nexus Venture Partners, Qatar Investment Authority, Tao Capital Partners
Price per Share
$xx.xx
Shares Outstanding
16,828,217
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Coatue, Exor Ventures, Illumina Ventures, Mubadala Capital, Nexus Venture Partners, Qatar Investment Authority, Tao Capital Partners
10/03/2023 Series B $106.23MM $xx.xx $275.56MM Abingworth, Ascenta Capital, Catalio Capital Management, Coatue, Freeflow, Gradiant Corporatoin, Illumina Ventures, Nexus Ventures, Nvidia, Orbimed, Sequoia Capital, Shanda, Tao Capital
Price per Share
$xx.xx
Shares Outstanding
42,904,185
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Ascenta Capital, Catalio Capital Management, Coatue, Freeflow, Gradiant Corporatoin, Illumina Ventures, Nexus Ventures, Nvidia, Orbimed, Sequoia Capital, Shanda, Tao Capital
07/14/2021 Series A-1 $2MM $xx.xx $173.61MM Catalio Capital Management, Coatue, Freeflow, Nexus Venture Partners, Orbimed, Sequoia Capital
Price per Share
$xx.xx
Shares Outstanding
1,053,462
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital Management, Coatue, Freeflow, Nexus Venture Partners, Orbimed, Sequoia Capital
07/14/2021 Series A $67.15MM $xx.xx $173.61MM Catalio Capital Management, Coatue, Freeflow, Nexus Venture Partners, Orbimed, Sequoia Capital
Price per Share
$xx.xx
Shares Outstanding
28,295,040
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital Management, Coatue, Freeflow, Nexus Venture Partners, Orbimed, Sequoia Capital
04/01/2020 Series Seed $2.52MM $xx.xx $8.4MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
7,231,110
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.